FEMY - Femasys Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Company Name, Ticker, Suppliers, else..

Femasys Inc (FEMY)

Other Ticker:

Sector • Healthcare Industry • Medical Equipment & Supplies

Industry • Medical Equipment & Supplies

Sector • Healthcare

Price: $1.1200 $0.00

0.000%

Day's High:	$1.13	Week Perf:	2.75 %
Day's Low:	$ 1.11	30 Day Perf:	5.66 %
Volume (M):	35	52 Wk High:	$ 4.75
Volume (M$):	$ 39	52 Wk Avg:	$1.22
Open:	$1.12	52 Wk Low:	$0.25

FEMY Charts & Quotes

FEMY Charts & Quotes

Company's Segments

Market Capitalization (Millions $)	25
Shares Outstanding (Millions)	22
Employees	-
Revenues (TTM) (Millions $)	1
Net Income (TTM) (Millions $)	-17
Cash Flow (TTM) (Millions $)	3
Capital Exp. (TTM) (Millions $)	0

Femasys Inc
Femasys Inc is a healthcare company based in Suwanee, Georgia, that focuses on developing innovative medical devices for women's health. The company specializes in creating non-surgical solutions for common gynecological procedures. Some of their products include the FemBloc Permanent Contraceptive System, which provides a non-hormonal, incision-less approach to tubal occlusion, and the FemVue Saline-Air Device, used to evaluate fallopian tube patency. Femasys Inc aims to improve women's healthcare by offering safe, effective, and minimally invasive solutions.

Company Address: 3950 Johns Creek Court Suwanee 30024 GA
Company Phone Number: 500-3910 Stock Exchange / Ticker: NASDAQ FEMY

Reports on Competition

List of Competitors

Competitors by Segment

Segment Growth

Growth Rates

Suppliers At a Glance

List of Suppliers

Suppliers Performance

Stock Performances by Major Competitors

5 Days	Decrease / Increase

• View Complete Report

Femasys Inc News

Partnership

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed for over $1.3M in Spanish Market

Published Wed, Sep 11 2024 12:30 PM UTC

Femasys Expands European Footprint with Strategic Distribution Partnerships, Despite Financial ChallengesFemasys Inc., a notable player in the healthcare technology sector, has recently secured strategic distribution partnerships to further the commercialization of its innovative women's reproductive healthcare product, FemaSeed, in the Spanish market. This development come...

Licensing Agreement

Femasys Inc. Gains FDA Clearance for FemChec, a Revolutionary Diagnostic Tool Enhancing Fallopian Tube Evaluation and...

Published Mon, Sep 9 2024 12:30 PM UTC

'Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check'In a significant advancement for women's health, Femasys Inc., a pioneering force in female healthcare solutions, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for FemChec. This groundbreaking contrast-...

Product Service News

Femasys Secures Groundbreaking CE Mark Approval, Paving the Way for Womens Health Innovations in Europe

Published Thu, Jun 20 2024 12:30 PM UTC

'Breaking Through: Femasys Secures CE Mark Approval for Women's Health Innovations'When it comes to addressing the significant unmet needs in women's healthcare, Femasys Inc. stands at the forefront. The Atlanta-based biomedical company recently achieved a significant milestone by receiving European Union Medical Device Regulation (EU MDR) certification and CE Mark approval ...

Management Announcement

Femasys Innovates Women's Reproductive Health, Meets White House Gender Policy Council, Faces Temporary Share Price Challenge

Published Thu, May 16 2024 12:30 PM UTC

Femasys CEO Meets with White House Gender Policy Council to Discuss Revolutionary Women's Reproductive Health Products, Impacting Share Price Negatively in Q2 2024
In a groundbreaking development, Kathy Lee-Sepsick, the CEO and Founder of Femasys, recently had the honor of meeting with the White House Gender Policy Council to discuss the Atlanta-based biomedical company'...

Femasys Inc

Femasys Inc. Faces Evanescence of Profitability as Orders Decrease in Q1 2024

As a financial journalist for the CSIMarket.com, I have been analyzing the recent financial results of Femasys Inc for the January to March 31 2024 fiscal time-frame. The company reported a decrease in revenue of -7.77% year on year, bringing it down to $0.27 million. This drop in revenue is in stark contrast to the on average growth seen in the Medical Equipment & Supplies sector during the same period. The company also reported a decrease in net shortfall, with a loss per share of $-0.17, down from $-0.18 per share in the previous reporting period.
Despite these financial challenges, Femasys Inc has not been sitting idle. The company recently announced the recruitment of a commercial team for their infertility portfolio and the pivotal trial of FemBloc for permanent non-surgical birth control continues. This move signifies their commitment to addressing significant unmet needs of women worldwide with innovative products.

FEMY's Valuation	Current
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	26.19
Price to Sales (Expected)	-
Price to Book	2.21
PEG (TTM)	-

FEMY's Financial Strength	Current
Quick Ratio	7.36
Working Capital Ratio	8.67
Leverage Ratio (MRQ)	0.59
Total Debt to Equity	0.42
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

Per Share	Current
Earnings (TTM)	-0.82 $
Revenues (TTM)	0.04 $
Cash Flow (TTM)	0.13 $
Cash	0.61 $
Book Value	0.51 $
Dividend (TTM)	0 $

FEMY's Efficiency	Current
Revenue per Employee (TTM)	-
Net Income per Employee (TTM)	-
Receivable Turnover Ratio (TTM)	9.15
Inventory Turnover Ratio (TTM)	0.37
Asset Turnover Ratio (TTM)	0.04

FEMY's Profitability Ratios	Current
Gross Margin (MRQ)	66.98 %
Operating Margin (MRQ)	-2023.69 %
Net Margin (MRQ)	-2115.08 %
Net Cash Flow Margin (MRQ)	-1946 %
Effective Tax Rate (TTM)	-

Management Effectiveness	Current
Return On Assets (TTM)	-
Return On Investment (TTM)	-
Return On Equity (TTM)	-
Dividend Yield	-
Pay out Ratio (TTM)	-

FEMY's Valuation
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	26.19
Price to Sales (Expected)	-
Price to Book	2.21
PEG (TTM)	-

Per Share
Earnings (TTM)	-0.82 $
Revenues (TTM)	0.04 $
Cash Flow (TTM)	0.13 $
Cash	0.61 $
Book Value	0.51 $
Dividend (TTM)	0 $

FEMY's Financial Strength
Quick Ratio	7.36
Working Capital Ratio	8.67
Leverage Ratio (MRQ)	0.59
Total Debt to Equity	0.42
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

FEMY's Efficiency
Revenue per Employee (TTM)	-
Net Income per Employee (TTM)	-
Receivable Turnover Ratio (TTM)	9.15
Inventory Turnover Ratio (TTM)	0.37
Asset Turnover Ratio (TTM)	0.04

FEMY's Profitability Ratio
Gross Margin (MRQ)	66.98 %
Operating Margin (MRQ)	-2023.69 %
Net Margin (MRQ)	-2115.08 %
Net Cash Flow Margin (MRQ)	-1946 %
Effective Tax Rate (TTM)	-

Management Effectiveness
Return On Assets (TTM)	-76.52 %
Return On Investment (TTM)	-93.73 %
Return On Equity (TTM)	-119.97 %
Dividend Yield	-
Pay out Ratio (TTM)	-

Femasys Inc's Segments

Femasys Inc Outlook

On March 28 2024 the Femasys Inc provided following guidance

Femasys Inc. has recently announced its financial r...

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright � 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com